Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants EUAs for Coronavirus Tests From Grifols, Visby Medical, Immunodiagnostic Systems

NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations for molecular SARS-CoV-2 tests from Grifols Diagnostic Solutions, Visby Medical, and Immunodiagnostic Systems.

Grifols' Procleix SARS-CoV-2 Assay uses transcription-mediated nucleic acid amplification to detect SARS-CoV-2 nucleic acid in anterior nasal, mid-turbinate nasal, nasopharyngeal, and oropharyngeal swab specimens, as well as nasopharyngeal washes/aspirates, nasal aspirates, and bronchoalveolar lavage. The test runs on the San Diego-based company's fully automated Procleix Panther System, which integrates processing, interpretation, and management of nucleic acid testing.

The assay may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

The Visby Medical COVID-19 Point of Care Test is a single-use, fully integrated RT-PCR assay designed to detect SARS-CoV-2 nucleic acid in nasopharyngeal, anterior nasal, or mid-turbinate swabs collected by a health care provider or in anterior nasal or mid-turbinate swabs self-collected under the supervision of a healthcare provider. Results are provided within 30 minutes after a sample is loaded into the testing device.

The assay may be used by labs CLIA-certified to perform high-, moderate-, or waived-complexity tests, as well as at the point of care in settings operating under a CLIA A Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Earlier this month, San Jose, California-based Visby won a $12.3 million contract from the US Department of Health and Human Services to develop a combination SARS-CoV-2/influenza test.

UK-based Immunodiagnostic Systems' IDS SARS-CoV-2 IgG is an automated chemiluminescent immunoassay designed to detect immunoglobulin G against SARS-CoV-2 in serum and plasma.

It may be used by any lab CLIA-certified to perform moderate- or high-complexity tests.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.